GTx, Inc (NASDAQ:GTXI) has unveiled results for its recent trial. It was a study to evaluate enobosarm in post-menopausal women struggling with stress urinary incontinence (SUI).The orally-administered enobosarm didn’t sufficiently separate from the placebo.
The turn of events
GTx, Inc outlines that it conducted the enobosarm treatment over a period of 12 weeks. It discovered that the percentage of patients with greater than 50% reduction were 57.7% for 1mg, 58.9% for 3mg and 52.7% for placebo. The tolerance associated with Enobosarm was remarkable according to the company. The cases of adverse events were minimal and quite similar across the various treatment groups.
The Executive Chairman of GTx Robert J. Wills said, “We are very disappointed that the ASTRID Trial did not achieve its primary endpoint. We plan to conduct a full review of all the data.”
Wills outlined that they had plans underway to carry out a full review of all the data. Besides that, the official thanked the study coordinators, physicians, patients and the entire GTx team. All these parties showed great support in the novel trial.
Focusing into the future
GTx currently seeks to assess the potential of SARDs .It hopes to achieve quite much with its ongoing preclinical program. The business guru says it counts on the selective androgen receptor degrader technology. If all moves according to plan, it might soon succeed on its quest to treat the castration-resistant prostate cancer.
GTx will have development candidates by the time the year comes to a close. The company plans to take them into the IND-enabling studies.
Stress urinary incontinence (SUI) is a serious condition that has caused great discomfort among women over the years. Most of them complain about the unintentional leakages of urine in the course of activities that increase abdominal pressure such as physical exercise, sneezing and coughing.
Reports indicate that SUI affects 35 percent of adult women who on a yearly basis move out to seek out treatment.
They come across a wide range of treatments ranging from the pelvic floor physical therapy to behavioral modification. This are however the initial treatment options.
